Watch BMRN. Know when insiders buy.
One email the day a filing lands. Free.
Work order
63
WATCH · insiders 25, shorts 100
Insiders, 90 days
−$1.2M
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
2 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $12.9BP/E 179.8DIV YIELD —FCF YIELD 5.73%REV TTM $3.4B +11.2%NET INCOME $73M −88.9%NET DEBT $3.3B52W 49.67 – 70.24SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $989.7M | +19.9% | 79.5% | $110.9M | $44.8M | −81.4% | 0.23 | $168.1M | $28.8M | $139.3M | Aug 6 |
| Q1 2026 · Mar 31 | $766.2M | +2.8% | 74.6% | $129.6M | $105.5M | −43.2% | 0.54 | $220.7M | $20.9M | $199.7M | May 5 |
| Q4 2025 · Dec 31derived | $874.6M | +17.0% | 68.5% | −$44.6M | −$46.6M | −137.3% | -0.24 | $99.6M | $40.7M | $58.9M | Feb 26 |
| Q3 2025 · Sep 30 | $776.1M | +4.1% | 82.0% | −$46.7M | −$30.7M | −129.0% | -0.16 | $368.7M | $28.4M | $340.2M | Oct 28 |
| Q2 2025 · Jun 30 | $825.4M | +15.9% | 81.8% | $276.9M | $240.5M | +124.4% | 1.23 | $185.3M | $17.1M | $168.2M | Aug 6 |
| Q1 2025 · Mar 31 | $745.1M | +14.8% | 79.7% | $223.9M | $185.7M | +109.4% | 0.95 | $174.4M | $16.8M | $157.6M | May 5 |
| Q4 2024 · Dec 31derived | $747.3M | +15.6% | 81.8% | $161.4M | $124.9M | +513.2% | 0.65 | $185.6M | $19.5M | $166.1M | Feb 26 |
| Q3 2024 · Sep 30 | $745.7M | +28.3% | 74.7% | $113.9M | $106.1M | +162.7% | 0.55 | $221.5M | $18.5M | $203M | Oct 28 |
| Q2 2024 · Jun 30 | $712M | — | 81.7% | $120.5M | $107.2M | — | 0.55 | $118.8M | $21.3M | $97.4M | Aug 5 |
| Q1 2024 · Mar 31 | $648.8M | — | 80.7% | $88.5M | $88.7M | — | 0.46 | $47M | $26.1M | $20.9M | May 2 |
| Q4 2023 · Dec 31derived | $646.2M | — | 78.7% | $27.3M | $20.4M | — | 0.10 | $27.5M | $28.9M | −$1.4M | Feb 26 |
| Q3 2023 · Sep 30 | $581.3M | — | 78.0% | $30.5M | $40.4M | — | 0.21 | $135.6M | $21.7M | $113.9M | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $3.2B | 77.7% | $409.5M | $348.9M | 10.8% | 1.80 | $828M | $103M | $725M | — | — |
| FY2024 · to Dec 31 | $2.9B | 79.7% | $484.2M | $426.9M | 15.0% | 2.21 | $572.8M | $85.4M | $487.4M | — | — |
| FY2023 · to Dec 31 | $2.4B | 78.0% | $185.8M | $167.6M | 6.9% | 0.87 | $159.3M | $96.7M | $62.6M | — | — |
| FY2022 · to Dec 31 | $2.1B | 76.0% | $161M | $141.6M | 6.8% | 0.75 | $175.9M | $121M | $54.9M | $0 | — |
| FY2021 · to Dec 31 | $1.8B | 74.5% | −$82.3M | −$64.1M | -3.5% | -0.35 | $304.5M | $95.6M | $209M | $0 | — |
| FY2020 · to Dec 31 | $1.9B | 71.8% | −$43.4M | $854M | 45.9% | 4.50 | $85.4M | $114.3M | −$28.9M | $50M | — |
Every number comes from BIOMARIN PHARMACEUTICAL INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.